RecruitingPhase 1Phase 2NCT06675422

JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)

JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE) - A Safety, Tolerability, and Efficacy Study

Sponsor

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Enrollment

20 participants

Start Date

Oct 9, 2024

Study Type

INTERVENTIONAL

Conditions

Systemic Lupus Erythematosus (SLE)

Summary

Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of active systemic lupus erythematosus (SLE)

Eligibility

Min Age: 14 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called JY231 injection for people with systemic lupus erythematosus (sle). The study is currently recruiting participants at 1 location. People eligible for this study include aged 14 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGJY231 injection

Dose escalation was carried out using the 3+3 principle and the mode of administration was intravenous.

Locations(1)

920th HJointLogistics

Kunming, Yunnan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06675422

Related Trials

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

NCT055671981 location

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

NCT068399761 location

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

NCT0717528564 locations

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

NCT060329231 location

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

NCT0633597913 locations